Remove 2015 Remove Licensing Remove Pharmacy
article thumbnail

Article FDA Thank You In proposed rule, FDA offers up a (surprisingly sparse) list of drugs that present demonstrable compounding difficulties

Agency IQ

FDA addressed the expanding practice of drug compounding in 1992 by issuing a compliance policy guide that clarified that pharmacies which compounded products at certain scales, for certain purposes, or without FDA approval were clearly operating “outside the bounds of traditional pharmacy practice.”

FDA 40
article thumbnail

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94 Read our analysis of that rule here and here. ] This rule also establishes standards for determining whether the major statement in these advertisements is presented in the manner required.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Life Sciences Thank You The cost of artificially short expiration dates: Worsened shortages, higher costs and more waste

Agency IQ

What happens when a drug is not stored in its original container or within a licensed facility? All of the evidence discussed thus far pertains to drugs that have been stored in ideal conditions and within the original container by a licensed facility. Enter the beyond-use date. In most states, this defers to the USP recommendation.

Science 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023

Agency IQ

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in December 2023

Agency IQ

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The following PDUFA dates were obtained from publicly available sources.

FDA 40
article thumbnail

FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)

The Pharma Data

“Since 2015, BARDA has partnered with Regeneron to develop a life-saving treatment for Ebola Zaire. Regeneron is actively working with non-governmental organizations and public health agencies to ensure continued access to Inmazeb in low- and middle-income countries.